Acknowledgements

The ChEMBL resources are made available due to funding from the following:

Current Awards

• Ongoing: The Member States of the European Molecular Biology Laboratory (EMBL)

• 2020-2024: Wellcome Trust (Strategic Award 218244/Z/19/Z)

• 2018-2023: Illuminating the Druggable Genome NIH grant 1U24CA224370-01

• 2014-2024: Open Targets

• 2020-2025: European Commission/IMI2 EUbOPEN: Enabling and unlocking biology in the OPEN (875510)

Past Awards

• 2014-2019: Wellcome Trust (Strategic Award WT086151/Z/08/Z).

• 2016-2022: European Commission Horizon 2020. Toxicity Testing and Risk Assessment in the 21st Century EU-ToxRisk (681002)

• 2015-2019: Coordinated Research Infrastructures Building Enduring Life-science Services CORBEL (654248)

• 2017-2022: European Commission/IMI2 eTRANSAFE - Enhacing TRANslational SAFEty Assessment through Integrative Knowledge Management (777365)

• 2017-2021: European Commission/IMI2/TransQST - Translational quantitative systems toxicology to improve the understanding of the safety of medicines (116030)

• 2013-2018: European Commission FP7 HeCaTos - Safety prediction (602156)

• 2009-2016: European Commission/IMI IMI eTox (115002)

• 2014-2016: Illuminating the Druggable Genome NIH grant 1U54CA189205-01

• 2008-2014: Chemogenomics at the EBI, WT Strategic award 086151/Z/08/Z

• 2012-2015: European Commission FP7 BioMedBridges (284209)

• 2014-2014: Pistoia Alliance Application of HELM Nomenclature to ChEMBL peptide content.

• 2012-2014: Medicines for Malaria Ventures - Malaria Data Deposition Portal

• 2012-2014: European Commission/IMI IMI Open PHACTS (115191)

• 2011-2014: European Commission FP7 DiXa (283775)

• 2011-2014: BBSRC/EPSRC/MRC SMSDrug.net - Chemical Biology Networking (EP/I037229/1)

• 2013-2013: Syngenta - Herbicide and Insecticide Data for ChEMBL

• 2011-2013: GSK - ADMET SARfari

• 2009-2013: European Commission ESFRI EU-OpenScreen (261861)

• 2010-2011: Pfizer - Druggability Analysis